Quarterly ResultAug 6, 2026, 07:08 AM
Korro Bio Q2 Net Loss $18.9M; Cash $137.9M; Pipeline Progress
AI Summary
Korro Bio reported a net loss of $18.9 million for Q2 2026, an improvement from $25.8 million in Q2 2025. The company ended the quarter with $137.9 million in cash, cash equivalents, and marketable securities, extending its cash runway into the second half of 2028. Significant pipeline progress includes receiving Orphan Drug Designation for KRRO-121 and nominating KRRO-111 as a development candidate for Alpha-1 Antitrypsin Deficiency. Additionally, Korro Bio entered an exchange agreement with Venrock Healthcare Capital Partners, surrendering 1,000,000 common shares for no consideration and issuing pre-funded warrants for the same amount.
Key Highlights
- Q2 2026 net loss was $18.9 million, down from $25.8 million in Q2 2025.
- Cash, cash equivalents, marketable securities totaled $137.9 million as of June 30, 2026.
- Company projects cash runway into the second half of 2028.
- R&D expenses decreased to $13.6 million in Q2 2026 from $20.1 million in Q2 2025.
- Received EMA Orphan Drug Designation for KRRO-121 for urea cycle disorders.
- Nominated KRRO-111 as development candidate for Alpha-1 Antitrypsin Deficiency.
- Exchanged 1,000,000 common shares for 1,000,000 pre-funded warrants with Venrock.
Price Impact
More from KRRO